^
Association details:
| Biomarker: | MET overexpression + EGFR mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
EP08.02-140 - MET Biomarker-based Preliminary Efficacy Analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC Post-Osimertinib
Published date:
07/12/2022
Excerpt:
SAVANNAH is a single-arm, PhII study in which patients with EGFRm NSCLC who have MET overexpression and/or amplification upon disease progression post-osimertinib received oral savolitinib 300/600mg once-daily (QD) or 300mg twice-daily, in combination with oral osimertinib 80mg QD....Efficacy in the IHC90+ and/or FISH10+ subgroup (ORR 49%, median DoR 9.3 months, median PFS 7.1 months) was improved compared to the overall population; particularly versus the subgroup without IHC90+ and/or FISH10+ status (ORR 9%, median DoR 6.9 months, median PFS 2.8 months) (Table).
Trial ID:
